The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
Abstract
:Simple Summary
Abstract
1. Introduction
2. Overview of T-Cell Differentiation, Polarization and Activation Status
3. The Hodgkin Reed-Sternberg Secretome: Combinatorial Signals for T-Cell Recruitment
4. The Spectrum of T-Helper Subsets in the cHL Microenvironment
5. Contribution and Localization of CD8+ T Cells in the cHL Microenvironment
6. Natural Killer Cells in cHL: Keeping Cytotoxicity in Check
7. Immunosuppressive Interactions Taking Place in the Neoplastic Niche
8. How HRS, T and NK Cells Predict Response to PD-1 Blockade
9. Translational Insights to Improve Immunotherapy Results
10. Concluding Remarks
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Connors, J.M.; Cozen, W.; Steidl, C.; Carbone, A.; Toppe, R.T.; Flechtner, H.H.; Bartlett, N.L. Hodgkin lymphoma. Nat. Rev. Dis. Primers 2020, 6, 61. [Google Scholar] [CrossRef] [PubMed]
- Hodgkin, T. On some morbid appearances of the absorbent glands and spleen. Med. Chir. Trans. 1832, 17, 68–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reed, D. On the pathological changes in Hodgkin’s disease with special reference to its relation to tuberculosis. John Hopkins Hosp. Rep. 1902, 10, 133–193. [Google Scholar]
- Sternberg, C. Über eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberkolose des lymphatischen Apparates. Z. Heilkd. 1898, 19, 21–90. [Google Scholar]
- Calabretta, E.; d’Amore, F.; Carlo-Stella, C. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. Int. J. Mol. Sci. 2019, 20, 5503. [Google Scholar] [CrossRef] [Green Version]
- Poppema, S. The Nature of the Lymphocytes Surrounding Reed-Sternberg Cells in Nodular Lymphocyte Predominance and in Other Types of Hodgkin’s Disease. Am. J. Pathol. 1989, 135, 351–357. [Google Scholar]
- Poppema, S.; Potters, M.; Visser, L.; van den Berg, A.M. Immune escape mechanisms in Hodgkin’s disease. Ann. Oncol. 1998, 9, S21–S24. [Google Scholar] [CrossRef]
- Poppema, S.; van den Berg, A.M. Interaction between host T cells and Reed–Sternberg cells in Hodgkin lymphomas. Semin. Cancer Biol. 2000, 10, 345–350. [Google Scholar] [CrossRef]
- Skinnider, B.F.; Mak, T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99, 4283–4297. [Google Scholar] [CrossRef] [Green Version]
- Greaves, P.; Clear, A.; Owen, A.; Iqbal, S.; Lee, A.; Matthews, J.; Wilson, A.; Calaminici, M.; Gribben, J.B. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 2013, 122, 2856–2863. [Google Scholar] [CrossRef]
- Marshall, N.A.; Christie, L.E.; Munro, L.R.; Culligan, D.J.; Johnston, P.W.; Barker, R.N.; Vickers, M.A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103, 1755–1762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gadalla, R.; Noamani, B.; MacLeod, B.L.; Dickson, R.J.; Guo, M.; Xu, W.; Lukhele, S.; Elsaesser, H.J.; Razak, A.R.A.; Hirano, N.; et al. Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. Front. Oncol. 2019, 9, 415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, X.; Zhang, L.; Chaudhry, A.; Rapaport, A.S.; Ouyang, W. Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis. J. Leuk. Biol. 2020, 107, 917–932. [Google Scholar] [CrossRef] [PubMed]
- Fang, P.; Li, X.; Dai, J.; Cole, L.; Camacho, J.A.; Zhang, Y.; Ji, Y.; Wang, J.; Yang, X.F.; Wang, H. Immune cell subset differentiation and tissue inflammation. J. Hematol. Oncol. 2018, 11, 97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kishton, R.J.; Sukumar, M.; Restifo, N.P. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 2017, 26, 94–109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vahedi, G.; Poholek, A.C.; Hand, T.W.; Laurence, A.; Kanno, Y.; O’Shea, J.J.; Hirahara, K. Helper T-cell identity and evolution of differential transcriptomes and epigenomes. Immunol. Rev. 2013, 252, 24–40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, J.; Yamane, H.; Paul, W.E. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 2010, 28, 445–489. [Google Scholar] [CrossRef] [Green Version]
- Peters, A.; Lee, Y.; Kuchroo, V.K. The many faces of Th17 cells. Curr. Opin. Immunol. 2011, 23, 702–706. [Google Scholar] [CrossRef]
- Murawski, M.R.; Litherland, S.A.; Clare-Salzler, M.J.; Davoodi-Semiromi, A. Upregulation of Foxp3 Expression in Mouse and Human Treg Is IL-2/STAT5 Dependent: Implications for the NOD STAT5B Mutation in Diabetes Pathogenesis. Ann. N. Y. Acad. Sci. 2006, 1079, 198–204. [Google Scholar] [CrossRef]
- Cader, F.Z.; Schackmann, R.C.J.; Hu, X.; Wienand, K.; Redd, R.; Chapuy, B.; Ouyang, J.; Paul, N.; Gjini, E.; Lipschitz, M.; et al. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood 2018, 132, 825–836. [Google Scholar] [CrossRef]
- Pizzolo, G.; Vinante, F.; Chilosi, M.; Romagnani, S.; Del Prete, G. CD30 Antigen and Cellular Biology of Reed-Sternberg Cells. Blood 1994, 84, 3983–3984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aldinucci, D.; Lorenzon, D.; Cattaruzza, L.; Pinto, A.; Gloghini, A.; Carbone, A.; Colombatti, A. Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int. J. Cancer 2008, 122, 769–776. [Google Scholar] [CrossRef] [PubMed]
- Machicote, A.; Belén, S.; Baz, P.; Billordo, L.A.; Fainboim, L. Human CD8+ HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+FoxP3+ cells suppress Immune Responses via PD-1/PD-L1 Axis. Front. Oncol. 2018, 9, 2788. [Google Scholar] [CrossRef] [PubMed]
- Casagrande, N.; Borghese, C.; Visser, L.; Mongiat, M.; Colombatti, A.; Aldinucci, D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica 2019, 104, 564–575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jundt, F.; Anagnostopoulos, I.; Bommert, K.; Emmerich, F.; Müller, G.; Foss, H.D.; Royer, H.D.; Stein, H.; Dörken, B. Hodgkin/Reed-Sternberg Cells Induce Fibroblasts to Secrete Eotaxin, a Potent Chemoattractant for T Cells and Eosinophils. Blood 1999, 94, 2065–2071. [Google Scholar] [CrossRef]
- Kong, S.; Kim, B.S.; Uhm, T.G.; Lee, W.; Lee, G.R.; Park, C.S.; Lee, C.H.; Chung, I.Y. Different GATA Factors Dictate CCR3 Transcription in Allergic Inflammatory Cells in a Cell Type-Specific Manner. J. Immunol. 2013, 190, 5747–5756. [Google Scholar] [CrossRef]
- van den Berg, A.; Visser, L.; Poppema, S. High Expression of the CC Chemokine TARC in Reed-Sternberg Cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin’s lymphoma. Am. J. Pathol. 1999, 154, 1685–1691. [Google Scholar] [CrossRef]
- Niens, M.; Visser, L.; Nolte, I.M.; van der Steege, G.; Diepstra, A.; Cordano, P.; Jarrett, R.F.; Te Meerman, G.J.; Poppema, S.; van den Berg, A. Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br. J. Haematol. 2008, 140, 527–536. [Google Scholar] [CrossRef]
- Ogura, M.; Ishida, T.; Hatake, K.; Taniwaki, M.; Ando, K.; Tobinai, K.; Fujimoto, K.; Yamamoto, K.; Miyamoto, T.; Uike, N.; et al. Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. J. Clin. Oncol. 2014, 32, 1157–1164. [Google Scholar] [CrossRef]
- Lamprecht, B.; Kreher, S.; Anagnostopoulos, I.; Jöhrens, K.; Monteleone, G.; Jundt, F.; Stein, H.; Janz, M.; Dörken, B.; Mathas, S. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T reg cells via regulation of MIP-3alpha. Blood 2008, 112, 3339–3347. [Google Scholar] [CrossRef]
- Ferrarini, I.; Rigo, A.; Zamò, A.; Vinante, F. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. Leuk. Lymphoma 2019, 60, 3395–3405. [Google Scholar] [CrossRef] [PubMed]
- Baumforth, K.R.N.; Birgersdotter, A.; Reynolds, G.M.; Wei, W.; Kapatai, G.; Flavell, J.R.; Kalk, E.; Piper, K.; Lee, S.; Machado, L.; et al. Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin’s Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells. Am. J. Pathol. 2008, 173, 195–204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Incrocci, R.; Barse, L.; Stone, A.; Vagvala, S.; Montesano, M.; Subramaniam, V.; Swanson-Mungerson, M. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton’s tyrosine kinase and STAT3. Virology 2017, 500, 96–102. [Google Scholar] [CrossRef] [PubMed]
- Murray, P.J.; Allen, J.E.; Biswas, S.K.; Fisher, E.A.; Gilroy, D.W.; Goerdt, S.; Gordon, S.; Hamilton, J.A.; Ivashkiv, L.B.; Lawrence, T.; et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity 2014, 41, 14–20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sarris, A.H.; Kliche, K.O.; Pethambaram, P.; Preti, A.; Tucker, S.; Jackow, C.; Messina, O.; Pugh, W.; Hagemeister, F.B.; McLaughlin, P.; et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin’s disease and are associated with inferior failure-free survival. Ann. Oncol. 1999, 10, 433–440. [Google Scholar] [CrossRef] [PubMed]
- Visco, C.; Vassilakopoulos, T.P.; Kliche, K.O.; Nadali, G.; Viviani, S.; Bonfante, V.; Medeiros, L.J.; Notti, P.; Rassidakis, G.Z.; Peethambaram, P.; et al. Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin’s Disease Treated with Radiotherapy. Leuk. Lymphoma 2004, 45, 2085–2092. [Google Scholar] [CrossRef]
- Machado, L.; Jarrett, R.; Morgan, S.; Murray, P.; Hunter, B.; Hamilton, E.; Crocker, J.; Thomas, W.; Steven, N.; Ismail, T.; et al. Expression and function of T cell homing molecules in Hodgkin’s lymphoma. Cancer Immunol. Immunother. 2009, 58, 85–94. [Google Scholar] [CrossRef]
- Fhu, C.W.; Graham, A.M.; Yap, C.T.; Al-Salam, S.; Castella, A.; Chong, S.M.; Lim, Y.C. Reed-Sternberg cell-derived lymphotoxin-a activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. Blood 2014, 124, 2973–2982. [Google Scholar] [CrossRef]
- Aldinucci, D.; Borghese, C.; Casagrande, N. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. Int. J. Mol. Sci. 2019, 20, 2416. [Google Scholar] [CrossRef] [Green Version]
- Levine, A.G.; Mendoza, A.; Hemmers, S.; Moltedo, B.; Niec, R.E.; Schizas, M.; Hoyos, B.E.; Putintseva, E.V.; Chaudhry, A.; Dikiy, S. Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature 2017, 546, 421–425. [Google Scholar] [CrossRef]
- Wein, F.; Weniger, M.A.; Höing, B.; Arnolds, J.; Hüttmann, A.; Hansmann, M.L.; Küppers, R. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma. Cancer Immunol. Res. 2017, 5, 1122–1133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schreck, S.; Friebel, D.; Buettner, M.; Distel, L.; Grabenbauer, G.; Young, L.S.; Niedobitek, G. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol. Oncol. 2009, 27, 31–39. [Google Scholar] [CrossRef] [PubMed]
- Duffield, A.S.; Ascierto, M.L.; Anders, R.A.; Taube, J.M.; Meeker, A.K.; Chen, S.; McMiller, T.L.; Phillips, N.A.; Haiying, X.; Ogurtsova, A.; et al. Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: Implications for immunotherapy. Blood Adv. 2017, 1, 1324–1334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aoki, T.; Chong, L.C.; Takata, K.; Milne, K.; Hav, M.; Colombo, A.; Chavez, E.A.; Nissen, M.; Wang, X.; Miyata-Takata, T.; et al. Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Cancer Discov. 2020, 10, 406–421. [Google Scholar] [CrossRef] [Green Version]
- Dehghani, M.; Kalani, M.; Golmoghaddam, H.; Ramzi, M.; Arandi, N. Aberrant peripheral blood CD4+CD25+FOXP3+ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma. Cancer Immunol. Immunother. 2020, 69, 1917–1928. [Google Scholar] [CrossRef]
- Pizzolo, G.; Vinante, F.; Chilosi, M.; Dallenbach, F.; Josimovic-Alasevic, O.; Diamantstein, T.; Stein, H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: Relationship with disease activity and clinical stage. Br. J. Haematol. 1990, 75, 282–284. [Google Scholar] [CrossRef]
- Liu, Y.; Sattarzadeh, A.; Diepstra, A.; Visser, L.; van den Berg, A. The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component. Semin. Cancer Biol. 2014, 24, 15–22. [Google Scholar] [CrossRef]
- Scheeren, F.A.; Diehl, S.A.; Smit, L.A.; Beaumont, T.; Naspetti, M.; Bende, R.J.; Blom, B.; Karube, K.; Ohshima, K.; van Noesel, C.J.M.; et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: Evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008, 111, 4706–4715. [Google Scholar] [CrossRef]
- Shahrara, S.; Pickens, S.R.; Dorfleutner, A.; Pope, R.M. IL-17 Induces Monocyte Migration in Rheumatoid Arthritis. J. Immunol. 2009, 182, 3884–3891. [Google Scholar] [CrossRef] [Green Version]
- Chetaille, B.; Betucci, F.; Finetti, P.; Esterni, B.; Stamatoullas, A.; Picquenot, J.M.; Copin, M.C.; Morschhauser, F.; Casasnovas, O.; Petrella, T.; et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009, 113, 2765–2775. [Google Scholar] [CrossRef] [Green Version]
- Zeng, H.; Zhang, R.; Jin, B.; Chen, L. Type 1 regulatory T cells: A new mechanism of peripheral immune tolerance. Cell Mol. Immunol. 2015, 12, 566–571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morales, O.; Mrizak, D.; François, V.; Mustapha, R.; Miroux, C.; Depil, S.; Decouvelaere, A.V.; Lionne-Huyghe, P.; Auriault, C.; de Launoit, Y.; et al. Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. Br. J. Haematol. 2014, 166, 875–890. [Google Scholar] [CrossRef] [PubMed]
- Chikuma, S. CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation. Curr. Top. Microbiol. Immunol. 2017, 410, 99–126. [Google Scholar] [PubMed]
- Patel, S.S.; Weirather, J.L.; Lipschitz, M.; Lako, A.; Chen, P.H.; Griffin, G.K.; Armand, P.; Shipp, M.A.; Rodig, S.J. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood 2019, 134, 2059–2069. [Google Scholar] [CrossRef] [PubMed]
- Liu, W.R.; Shipp, M.A. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 2017, 130, 2265–2270. [Google Scholar] [CrossRef] [Green Version]
- Jones, K.; Wockner, L.; Brennan, R.M.; Keane, C.; Chattopadhyay, P.K.; Roederer, M.; Price, D.A.; Cole, D.K.; Hassan, B.; Beck, K.; et al. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma. Clin. Exp. Immunol. 2016, 183, 206–220. [Google Scholar] [CrossRef] [Green Version]
- Gandhi, M.K.; Lambley, E.; Duraiswamy, J.; Dua, U.; Smith, C.; Elliott, S.; Gill, D.; Marlton, P.; Seymour, J.; Khanna, R. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006, 108, 2280–2289. [Google Scholar] [CrossRef]
- van der Leun, A.M.; Thommen, D.S.; Schumacher, T.N. CD8+ T cell states in human cancer: Insights from single-cell analysis. Nat. Rev. Cancer 2020, 20, 218–232. [Google Scholar] [CrossRef]
- Le, K.S.; Amé-Thomas, P.; Tarte, K.; Gondois-Rey, F.; Granjeaud, S.; Orlanducci, F.; Foucher, E.D.; Broussais, F.; Bouabdallah, R.; Fest, T.; et al. CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas. Blood Adv. 2018, 2, 1889–1900. [Google Scholar] [CrossRef]
- Silina, K.; Soltermann, A.; Attar, F.M.; Casanova, R.; Uckeley, Z.M.; Thut, H.; Wandres, M.; Isajevs, S.; Cheng, P.; Curioni-Fontecedro, A.; et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 2018, 78, 1308–1320. [Google Scholar] [CrossRef] [Green Version]
- Gandhi, M.K.; Moll, G.; Smith, C.; Dua, U.; Lambley, E.; Ramuz, O.; Devinder, G.; Marlton, P.; Seymour, J.F.; Khanna, R. Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007, 110, 1326–1329. [Google Scholar] [CrossRef] [PubMed]
- O’Connor, G.M.; Hart, O.M.; Gardiner, C.M. Putting the natural killer cell in its place. Immunology 2005, 117, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Reichel, J.; Chadburn, A.; Rubinstein, P.G.; Giulino-Roth, L.; Tam, W.; Liu, Y.; Gaiolla, R.; Eng, K.; Brody, J.; Inghirami, G.; et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015, 125, 1061–1072. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chiu, J.; Ernst, D.M.; Keating, A. Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Front. Immunol. 2018, 9, 267. [Google Scholar] [CrossRef] [PubMed]
- Schröder, M.; Meisel, C.; Buhl, K.; Profanter, N.; Sievert, N.; Volk, H.D.; Grütz, G. Different Modes of IL-10 and TGF-β to Inhibit Cytokine-Dependent IFN-γ Production: Consequences for Reversal of Lipopolysaccharide Desensitization. J. Immunol. 2003, 170, 5260–5267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gooding, R.; Riches, P.; Dadian, G.; Moore, J.; Gore, M. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br. J. Cancer. 1995, 72, 452–455. [Google Scholar] [CrossRef] [Green Version]
- Medvedev, A.E.; Johnsen, A.C.; Haux, J.; Steinkjer, B.; Egeberg, K.; Lynch, D.H.; Sundan, A.; Espevik, T. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine 1997, 9, 394–404. [Google Scholar] [CrossRef]
- Carey, C.D.; Gusenleitner, D.; Lipschitz, M.; Roemer, M.G.M.; Stack, E.C.; Gjini, E.; Hu, X.; Redd, R.; Freeman, G.J.; Neuberg, D.; et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 2017, 130, 2420–2430. [Google Scholar] [CrossRef]
- Cooper, M.A.; Fehniger, T.A.; Caligiuri, M.A. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22, 633–640. [Google Scholar] [CrossRef]
- Vari, F.; Arpon, D.; Keane, C.; Hertzberg, M.S.; Talaulikar, D.; Jain, S.; Cui, Q.; Han, E.; Tobin, J.; Bird, R.; et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 2018, 131, 1809–1819. [Google Scholar] [CrossRef] [Green Version]
- Stannard, K.A.; Lemoine, S.; Waterhouse, N.J.; Vari, F.; Chatenoud, L.; Gandhi, M.K.; Martinet, L.; Smyth, M.J.; Guillerey, C. Human peripheral blood DNAM-1 neg NK cells are a terminally differentiated subset with limited effector functions. Blood Adv. 2019, 3, 1681–1694. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.W.; Ren, Y.J.; Marella, M.; Wang, M.; Hartke, J.; Couto, S.S. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma. J. Immunol. Methods 2020, 478, 112714. [Google Scholar] [CrossRef] [PubMed]
- Baharlou, H.; Canete, N.P.; Cunningham, A.L.; Harman, A.N.; Patrick, E. Mass Cytometry Imaging for the Study of Human Diseases-Applications and Data Analysis Strategies. Front. Immunol. 2019, 10, 2657. [Google Scholar] [CrossRef] [PubMed]
- Reinke, S.; Bröckelmann, P.J.; Iaccarino, I.; Garcia-Marquez, M.A.; Borchmann, S.; Jochims, F.; Kotrova, M.; Pal, K.; Brüggemann, M.; Hartmann, E.; et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood 2020. [Google Scholar] [CrossRef]
- Veldman, J.; Visser, L.; Huberts-Kregel, M.; Muller, N.; Hepkema, B.; Van den Berg, A.; Diepstra, A. Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. Blood 2020. [Google Scholar] [CrossRef]
- Boussiotis, V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N. Engl. J. Med. 2016, 375, 1767–1778. [Google Scholar] [CrossRef] [Green Version]
- Pentcheva-Hoang, T.; Egen, J.G.; Wojnoonski, K.; Allison, J.P. B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse. Immunity 2004, 21, 401–413. [Google Scholar] [CrossRef] [Green Version]
- Long, L.; Zhang, X.; Chen, F.; Pan, Q.; Phiphatwatchara, P.; Zeng, Y.; Chen, H. The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy. Genes Cancer 2018, 9, 176–189. [Google Scholar] [CrossRef] [Green Version]
- Jalali, S.; Price-Troska, T.; Bothun, C.; Villasboas, J.; Kim, H.J.; Yang, Z.Z.; Novak, A.J.; Dong, H.; Ansell, S.M. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 2019, 9, 22. [Google Scholar] [CrossRef]
- Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N. Engl. J. Med. 2015, 372, 311–319. [Google Scholar] [CrossRef] [Green Version]
- Armand, P.; Shipp, M.A.; Ribrag, V.; Michot, J.; Zinzani, P.L.; Kuruvilla, J.; Snyder, E.S.; Ricart, A.D.; Balakumaran, A.; Rose, S.; et al. Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J. Clin. Oncol. 2016, 34, 3733–3739. [Google Scholar] [CrossRef]
- Armand, P.; Engert, A.; Younes, A.; Fanale, M.; Santoro, A.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J. Clin. Oncol. 2018, 36, 1428–1439. [Google Scholar] [CrossRef]
- Chen, R.; Zinzani, P.L.; Lee, H.J.; Armand, P.; Johnson, N.A.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulos, T.P.; et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 2019, 134, 1144–1153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roemer, M.G.M.; Redd, R.A.; Cader, F.Z.; Pak, C.J.; Abdelrahman, S.; Ouyang, J.; Sasse, S.; Younes, A.; Fanale, M.; Santoro, A.; et al. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J. Clin. Oncol. 2018, 36, 942–950. [Google Scholar] [CrossRef]
- Derenzini, E.; Lemoine, M.; Buglio, D.; Katayama, H.; Ji, Y.; Davis, R.E.; Sen, S.; Younes, A. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011, 1, e46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagasaki, J.; Togashi, Y.; Sugawara, T.; Itami, M.; Yamauchi, N.; Yuda, J.; Sugano, M.; Ohara, Y.; Minami, Y.; Nakamae, H.; et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 2020, 4, 4069–4082. [Google Scholar] [CrossRef] [PubMed]
- Cader, F.Z.; Hu, X.; Goh, W.L.; Wienand, K.; Ouyang, J.; Mandato, E.; Redd, R.; Lawton, L.N.; Chen, P.H.; Weirather, J.L.; et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat. Med. 2020, 26, 1468–1479. [Google Scholar] [CrossRef]
- Kline, J.; Godfrey, J.; Ansell, S.M. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood 2020, 135, 523–533. [Google Scholar] [CrossRef]
- Koyama, S.; Akbay, E.A.; Li, Y.Y.; Herter-Sprie, G.S.; Buczkowski, K.A.; Richards, W.G.; Gandhi, L.; Redig, A.J.; Rodig, S.J.; Asahina, H.; et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 2016, 7, 10501. [Google Scholar] [CrossRef]
- Pauken, K.E.; Sammons, M.A.; Odorizzi, P.M.; Manne, S.; Godec, J.; Khan, O.; Drake, A.M.; Chen, Z.; Sen, D.R.; Kurachi, M.; et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 2016, 354, 1160–1165. [Google Scholar] [CrossRef] [Green Version]
- Ghoneim, H.E.; Fan, Y.; Moustaki, A.; Abdelsamed, H.A.; Dash, P.; Dogra, P.; Carter, R.; Awad, W.; Neale, G.; Thomas, P.G.; et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell 2017, 170, 142–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nie, J.; Wang, C.; Liu, Y.; Yang, Q.; Mei, Q.; Dong, L.; Li, X.; Liu, J.; Ku, W.; Zhang, Y.; et al. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. J. Clin. Oncol. 2019, 37, 1479–1489. [Google Scholar] [CrossRef] [PubMed]
- Armand, P.; Lesokhin, A.; Borrello, I.; Timmerman, J.; Gutierrez, M.; Zhu, L.; Popa McKiver, M.; Ansell, S.M. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia 2020. [Google Scholar] [CrossRef] [PubMed]
- Rodig, S.J.; Gusenleitner, D.; Jackson, D.G.; Gjini, E.; Giobbie-hurder, A.; Jin, C.; Jin, C.; Chang, H.; Lovitch, S.B.; Horak, C.; et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 2018, 10, eaar3342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burova, E.; Hermann, A.; Dai, J.; Ullman, E.; Halasz, G.; Potocky, T.; Hong, S.; Liu, M.; Allbritton, O.; Woodruff, A.; et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol. Cancer Ther. 2019, 18, 2051–2062. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, X.; Huang, X.; Chen, X.; Liu, J.; Wu, C.; Pu, Q.; Wang, Y.; Kang, X.; Zhou, L. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs 2019, 11, 1139–1148. [Google Scholar] [CrossRef]
- Ascierto, P.A.; Melero, I.; Bhatia, S.; Bono, P.; Sanborn, R.E.; Lipson, E.J.; Callahan, M.K.; Gajewski, T.; Gomez-Roca, C.A.; Hodi, F.S.; et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J. Clin. Oncol. 2017, 35 (Suppl. 15), 9520. [Google Scholar]
- Rothe, A.; Sasse, S.; Topp, M.S.; Eichenauer, D.A.; Hummel, H.; Reiners, K.S.; Dietlein, M.; Kuhnert, G.; Kessler, J.; Buerkle, C.; et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015, 125, 4024–4031. [Google Scholar] [CrossRef]
- Bartlett, N.L.; Herrera, A.F.; Domingo-Domenech, E.; Mehta, A.; Forero-Torres, A.; Garcia-Sanz, R.; Armand, P.; Devata, S.; Rodriguez Izquierdo, A.; Lossos, I.S.; et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2020. [Google Scholar] [CrossRef]
- Janik, J.E.; Morris, J.C.; O’Mahony, D.; Pittaluga, S.; Jaffe, E.S.; Redon, C.E.; Bonner, W.M.; Brechbiel, M.W.; Paik, C.H.; Whatley, M.; et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma. Proc. Natl. Acad. Sci. USA 2015, 112, 13045–13050. [Google Scholar] [CrossRef] [Green Version]
- Hamadani, M.; Collins, G.P.; Samaniego, F.; Spira, A.I.; Davies, A.; Radford, J.; Caimi, P.; Menne, T.; Boni, J.; Cruz, H.; et al. Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. Blood 2018, 132 (Suppl. 1), 928. [Google Scholar] [CrossRef]
- Roswarski, J.; Roschewski, M.; Lucas, A.; Melani, C.; Pittaluga, S.; Jaffe, E.S.; Steinberg, S.M.; Waldmann, T.A.; Wilson, W.H. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH- R in aggressive peripheral T-cell lymphomas. Leuk. Lymphoma 2018, 59, 1466–1469. [Google Scholar] [CrossRef] [PubMed]
- Diefenbach, C.S.; Hong, F.; Ambinder, R.F.; Cohen, J.B.; Robertson, M.J.; David, K.A.; Advani, R.H.; Fenske, T.S.; Barta, S.K.; Palmisiano, N.D.; et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020, 7, e660–e670. [Google Scholar] [CrossRef]
- Hansen, H.P.; Engels, H.M.; Dams, M.; Paes Leme, A.F.; Pauletti, B.A.; Simhadri, V.L.; Dürkop, H.; Reiners, K.S.; Barnert, S.; Engert, A.; et al. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin’s lymphoma. J. Pathol. 2014, 232, 405–414. [Google Scholar] [CrossRef] [PubMed]
- Ramos, C.A.; Grover, N.S.; Beaven, A.W.; Lulla, P.D.; Wu, M.; Ivanova, A.; Wang, T.; Shea, T.S.; Rooney, C.M.; Dittus, C.; et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J. Clin. Oncol. 2020, 38, 3794–3804. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ferrarini, I.; Rigo, A.; Visco, C.; Krampera, M.; Vinante, F. The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. Cancers 2020, 12, 3757. https://doi.org/10.3390/cancers12123757
Ferrarini I, Rigo A, Visco C, Krampera M, Vinante F. The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. Cancers. 2020; 12(12):3757. https://doi.org/10.3390/cancers12123757
Chicago/Turabian StyleFerrarini, Isacco, Antonella Rigo, Carlo Visco, Mauro Krampera, and Fabrizio Vinante. 2020. "The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment" Cancers 12, no. 12: 3757. https://doi.org/10.3390/cancers12123757